Form 4 Filing for Avalo Therapeutics, Inc.

On April 29, 2026, and April 30, 2026, Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., sold a total of 16,915 shares of common stock. The sales were executed under a Rule 10b5-1 trading plan adopted on November 12, 2025. The transactions occurred in multiple parts, with prices ranging from $12.61 to $13.54 per share. Following these transactions, Mr. Sullivan owns 423 shares of common stock directly. The filing indicates that detailed information regarding the number of shares sold at each specific price within the reported ranges will be provided upon request by the Issuer, any security holder, or the SEC staff.